Welcome to the Utah Chapter of the American College of Cardiology
|
Ed Miner, MD, FACC Utah, Chapter President ACC Governor, Utah |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit:
ACC Rockies Chapter Meeting 2025
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- Are Cardiac Myosin Inhibitors the Real Deal? Aficamten vs. Beta-Blocker MonotherapyHypertrophic cardiomyopathy (HCM) has become increasingly prevalent worldwide, especially in the era of genetic screening. However, the recent introduction of cardiac myosin inhibitors (CMIs) and their proven efficacy in reducing the degree of left ventricular outflow tract obstruction (LVOTO)...
- ACCEL Lite: NOTIFY-PICTURE Trial: Real-Time Notification of AI-Derived Incidental CAC on Statin InitiationIn this interview, C. Noel Bairey Merz MD, MACC and Ramzi Dudum MD, FACC discuss the NOTIFY-PICTURE Trial: Effects of Real-Time Notification of AI-Detected Incidental Coronary Artery Calcium on Statin Prescription.
- Sports and Exercise Cardiology Highlights From the American Heart Association Scientific Sessions 2025A central sports cardiology session at the 2025 American Heart Association (AHA) Scientific Sessions, titled "Competitive Sports Participation for Athletes with Heart Disease: New Guidance and Future Directions," highlighted major updates from the 2025 AHA/American College of Cardiology (ACC) scientific statement on Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities.
- EVOLUT LOW RISK: Self-Expanding TAVR vs. Surgery at Six Years in Low-Risk Patients With ASSix years after undergoing either surgery or TAVR with a CoreValve, Evolut R or Evolut PRO, low-risk patients with aortic stenosis (AS) experienced no significant differences in terms of all-cause mortality or disabling stroke, according to findings from the Evolut Low Risk trial published in JACC. However, researchers observed higher reintervention rates among those assigned […]
- ACC Statement Opposes Legislative Mandates For Universal ECG Screening in Competitive AthletesLegislative mandates for universal electrocardiogram (ECG) screening in competitive athletes pose potential harm and unintended consequences, drawing attention and resources away from emergency action plan (EAP) implementation, an effective intervention for saving athletes' lives...